Because of the precision it offers, NanoKnife is safe to perform near critical structures such as the gallbladder, diaphragm, bile ducts, bowel, and major blood vessels. It can be used to treat tumors in or near the liver, pancreas, kidney, retroperitoneum, adrenal glands, lymph nodes, pelvic or other soft tissue masses. The procedure offers an array of benefits to the patient, including minimal pain, few side effects and a short hospital stay since it is a minimally invasive procedure as opposed to open surgery. Additionally, the procedure can also be repeated if new tumors develop.
"This is an exciting advance that allows us to wage a better war against cancers that previously have had few options for treatment," said Yoo. "As a cancer hospital, we are committed to offering a wide range of treatment options so we can offer patients individual treatment plans based on their unique cancer."
About NanoKnife The NanoKnife was approved by the U.S. Food and Drug Administration of surgical ablation of soft tissue and is made by AngioDynamics, a company based in Queensbury, New York. For More information at cancercenter.com
About Cancer Treatment Centers of America®Cancer Treatment Centers of America, Inc. (CTCA) is a national network of hospitals focusing on complex and advanced stage cancer. CTCA offers a comprehensive, fully integrated approach to cancer treatment and serves patients from all 50 states at facilities located in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Known for delivering the Mother Standard® of care and Patient Empowerment Medicine®, CTCA provides patients with information about cancer and their treatment options so they can control their treatment decisions. For more information about CTCA, go to www.cancercenter.com.SOURCE Cancer Treatment Centers of America